Scaling up interventions: findings and lessons learned from an external evaluation of Niger's National Initiative to reduce postpartum hemorrhage.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
24 Oct 2019
Historique:
received: 20 06 2019
accepted: 12 09 2019
entrez: 26 10 2019
pubmed: 28 10 2019
medline: 26 3 2020
Statut: epublish

Résumé

Niger has one of the highest maternal mortality ratios in Sub Saharan Africa, of which postpartum hemorrhage is the leading cause. In 2014, Health and Development International and the Ministry of Health of Niger launched an initiative to introduce and scale-up three PPH interventions in health facilities nationwide: misoprostol, uterine balloon tamponade, and the non-pneumatic anti-shock garment. A two-phase mixed-methods evaluation was conducted to assess implementation of the initiative. Health facility assessments, provider interviews, and household surveys were conducted in May 2016 and November 2017. All evaluation facilities received misoprostol prevention doses. However, shortages in misoprostol treatment doses, UBT kits, and NASG stock were documented. Health provider training increased while knowledge of each PPH intervention varied. Near-universal uterotonic coverage for PPH prevention and treatment was achieved and sustained throughout the evaluation period. Use of UBT and NASG to manage PPH was rare and differed by health facility type. Among community deliveries, fewer than 22% of women received misoprostol at antenatal care for self-administered prophylaxis. Among those who did, almost all reported taking the drugs for PPH prevention in each phase. This study is the first external evaluation of a comprehensive PPH program taking misoprostol, UBT, and NASG to national scale in a low resource setting. Although gaps in service delivery were identified, results demonstrate the complexities of training, managing stock, and implementing system-wide interventions to reach women in varying contexts. The experience provides important lessons for other countries as they develop and expand evidence-based programs for PPH care.

Sections du résumé

BACKGROUND BACKGROUND
Niger has one of the highest maternal mortality ratios in Sub Saharan Africa, of which postpartum hemorrhage is the leading cause. In 2014, Health and Development International and the Ministry of Health of Niger launched an initiative to introduce and scale-up three PPH interventions in health facilities nationwide: misoprostol, uterine balloon tamponade, and the non-pneumatic anti-shock garment.
METHODS METHODS
A two-phase mixed-methods evaluation was conducted to assess implementation of the initiative. Health facility assessments, provider interviews, and household surveys were conducted in May 2016 and November 2017.
RESULTS RESULTS
All evaluation facilities received misoprostol prevention doses. However, shortages in misoprostol treatment doses, UBT kits, and NASG stock were documented. Health provider training increased while knowledge of each PPH intervention varied. Near-universal uterotonic coverage for PPH prevention and treatment was achieved and sustained throughout the evaluation period. Use of UBT and NASG to manage PPH was rare and differed by health facility type. Among community deliveries, fewer than 22% of women received misoprostol at antenatal care for self-administered prophylaxis. Among those who did, almost all reported taking the drugs for PPH prevention in each phase.
CONCLUSIONS CONCLUSIONS
This study is the first external evaluation of a comprehensive PPH program taking misoprostol, UBT, and NASG to national scale in a low resource setting. Although gaps in service delivery were identified, results demonstrate the complexities of training, managing stock, and implementing system-wide interventions to reach women in varying contexts. The experience provides important lessons for other countries as they develop and expand evidence-based programs for PPH care.

Identifiants

pubmed: 31651264
doi: 10.1186/s12884-019-2502-5
pii: 10.1186/s12884-019-2502-5
pmc: PMC6814039
doi:

Substances chimiques

Oxytocics 0
Misoprostol 0E43V0BB57

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

379

Subventions

Organisme : Bill & Melinda Gates Foundation
ID : OPPGH5295
Pays : United States

Références

Int J Gynaecol Obstet. 2012 Jan;116(1):1-3
pubmed: 22078140
BJOG. 2014 Feb;121(3):319-25
pubmed: 24283350
J Health Popul Nutr. 2011 Apr;29(2):81-91
pubmed: 21608417
Health Policy Plan. 2016 Feb;31(1):102-13
pubmed: 25797470
Acta Obstet Gynecol Scand. 2008;87(6):652-61
pubmed: 18568465
Reprod Health. 2017 Oct 27;14(1):139
pubmed: 29078777
PLoS One. 2016 Mar 03;11(3):e0150739
pubmed: 26938211
BMC Pregnancy Childbirth. 2016 Apr 01;16:69
pubmed: 27036886
Int J Gynaecol Obstet. 2016 Jun;133(3):261-5
pubmed: 27158098
Int J Gynaecol Obstet. 2010 Mar;108(3):276-81
pubmed: 20053399
Int J Gynaecol Obstet. 2019 Mar;144(3):290-296
pubmed: 30582753
BMJ Open. 2017 Sep 1;7(9):e016590
pubmed: 28864699
Glob Public Health. 2018 Aug;13(8):1081-1097
pubmed: 28357885
Int J Gynaecol Obstet. 2016 Jun;133(3):301-6
pubmed: 26971258
BMC Pregnancy Childbirth. 2014 Jun 04;14:189
pubmed: 24894566
BMC Pregnancy Childbirth. 2017 Jun 5;17(1):169
pubmed: 28583092
Int J Gynaecol Obstet. 2014 Apr;125(1):53-5
pubmed: 24447412
BMC Pregnancy Childbirth. 2013 Feb 20;13:44
pubmed: 23421792
Int J Gynaecol Obstet. 2010 Mar;108(3):282-8
pubmed: 20034628
J Midwifery Womens Health. 2014 Jan;59 Suppl 1:S83-90
pubmed: 24588920
BMC Pregnancy Childbirth. 2015 Sep 14;15:219
pubmed: 26370443
Int J Gynaecol Obstet. 2014 Nov;127(2):183-8
pubmed: 25051905
Soc Sci Med. 2014 Nov;121:30-8
pubmed: 25306407
J Midwifery Womens Health. 2014 Jan;59 Suppl 1:S73-82
pubmed: 24588919
Int J Womens Health. 2014 Apr 08;6:389-93
pubmed: 24748820
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD009336
pubmed: 22336866

Auteurs

Meighan Mary (M)

Gynuity Health Projects, 220 East 42nd Street Suite 710, New York, NY, 10017, USA. mtarnagada@gynuity.org.

Ayisha Diop (A)

Gynuity Health Projects, 220 East 42nd Street Suite 710, New York, NY, 10017, USA.

Wendy R Sheldon (WR)

Gynuity Health Projects, 220 East 42nd Street Suite 710, New York, NY, 10017, USA.

Aichatou Yenikoye (A)

Gynuity Health Projects, 220 East 42nd Street Suite 710, New York, NY, 10017, USA.

Beverly Winikoff (B)

Gynuity Health Projects, 220 East 42nd Street Suite 710, New York, NY, 10017, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH